Melnick et al. developed a series of PROTACs targeting MALT1 that demonstrated selective killing effects in ABC-DLBCL, compared to germinal center B-Cell DLBCL (GCB-DLBCL), degrading over 50% of MALT1 protein and suppressing NF-κB activation.327 In addition, Wang et al. showed that MALT1 can contribute to ibrutinib resistance through bypassing BTK/CARD11 signaling.2 Dual knockdown of BTK and MALT1 significantly enhanced antitumor effects in ibrutinib-resistant MCL cell lines. Here, MALT1 is linked to aneurysmal bone cyst.